A rapid health technology assessment of brentuximab vedotin in therapy for relapse and refractory classic Hodgkin lymphoma

doi:10.3969/j.issn.1672-3384.2025.04.011

Xinyi CHEN, Chengcheng ZHAO, Qing XI

Clinical Medication Journal ›› 2025, Vol. 23 ›› Issue (4) : 60-65.

PDF(457 KB)

Clinical Medication Journal ›› 2025, Vol. 23 ›› Issue (4) : 60-65. DOI: 10.3969/j.issn.1672-3384.2025.04.011

Original Article

A rapid health technology assessment of brentuximab vedotin in therapy for relapse and refractory classic Hodgkin lymphoma

{{article.zuoZhe_EN}}

Author information +

History +

HeighLight

Abstract

Key words

QR code of this article

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

{{article.zuoZheEn_L}}. {{article.title_en}}[J]. {{journal.qiKanMingCheng_EN}}, 2025, 23(4): 60-65 https://doi.org/10.3969/j.issn.1672-3384.2025.04.011

References

List( Publishing order | Descend order by publishing year | Descend order by cited within ) Chart analysis

References

Funding

RIGHTS & PERMISSIONS

PDF(457 KB)

Accesses

Citation

Detail

Sections

Recommended

Received	Published
2024-12-26	2025-04-10
Issue Date
2025-04-28

Please choose a citation manager

Content to export